Development of an insect metalloproteinase inhibitor drug carrier system for application in chronic wound infections

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 11, 2015, Pages 1481-1491

  Eisenhardt, Michaela ^a   Dobler, Dorota ^a   Schlupp, Peggy ^a   Schmidts, Thomas ^a   Salzig, Mark ^b   Vilcinskas, Andreas ^b   Salzig, Denise ^a   Czermak, Peter ^a   Keusgen, Michael ^c   Runkel, Frank ^a  

^a UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

hydrogel; insect metalloproteinase inhibitor IMPI; microbial metalloproteinase; poloxamer 407; protein drug delivery; wound dressing

Indexed keywords

2 PHENOXYETHANOL; 4 HYDROXYBENZOIC ACID ESTER; APROTININ; BOVINE SERUM ALBUMIN; CITRIC ACID; DRUG CARRIER; GLUTATHIONE TRANSFERASE; GLYCEROL; HYALURONIC ACID; LYSOZYME; MACROGOL; METALLOPROTEINASE INHIBITOR; POLOXAMER; PROPYLENE GLYCOL; SORBATE POTASSIUM; THERMOLYSIN; CASEIN; EXCIPIENT; HYDROGEL; INSECT PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; VISCOELASTIC SUBSTANCE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; ESCHERICHIA COLI; FLUORESCENCE ANALYSIS; GELATION; GELLING POINT; HYDROGEL; IC50; NOCARDIA BRASILIENSIS; NONHUMAN; PH; PHYSICAL PARAMETERS; PSEUDOMONAS AERUGINOSA; SKIN TEMPERATURE; STAPHYLOCOCCUS AUREUS; VISCOELASTICITY; WOUND DRESSING; WOUND INFECTION; ANIMAL; CHEMISTRY; DRUG STORAGE; FLOW KINETICS; FLUORESCENCE; MOTH; TIME FACTOR;

ANIMALS; CASEINS; DRUG CARRIERS; DRUG LIBERATION; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FLUORESCENCE; GLUTATHIONE TRANSFERASE; HYDROGELS; INSECT PROTEINS; MATRIX METALLOPROTEINASE INHIBITORS; MOTHS; POLOXAMER; RHEOLOGY; TIME FACTORS; VISCOELASTIC SUBSTANCES; WOUND INFECTION;

EID: 84945479177     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12452     Document Type: Article

References (52)

1. Flour M, Degreef H,. Pharmacological treatment of wounds. Semin Cutan Med Surg, Elsevier 1998; 17: 260-265.
2. Hutchinson J, Lawrence J,. Wound infection under occlusive dressings. J Hosp Infect 1991; 17: 83-94.
3. Miyoshi S-I, Shinoda S,. Microbial metalloproteases and pathogenesis. Microbes Infect 2000; 2: 91-98.
4. Vilcinskas A,. Anti-infective therapeutics from the lepidopteran model host galleria mellonella. Curr Pharm Des 2011; 17: 1240-1245.
5. Wedde M, et al. The insect metalloproteinase inhibitor gene of the lepidopteran galleria mellonella encodes two distinct inhibitors. Biol Chem 2007; 388: 119-127.
6. Wedde M, et al. Purification and characterization of an inducible metalloprotease inhibitor from the hemolymph of greater wax moth larvae, galleria mellonella. Eur J Biochem 1998; 255: 535-543.
7. Vilcinskas A, Wedde M,. Insect inhibitors of metalloproteinases. IUBMB Life 2002; 54: 339-343.
8. Clermont A, et al. Cloning and expression of an inhibitor of microbial metalloproteinases from insects contributing to innate immunity. Biochem J 2004; 382: 315-322.
9. Boateng JS, et al. Wound healing dressings and drug delivery systems: a review. J Pharm Sci 2008; 97: 2892-2923.
10. Faulkner DM,. A new stable pluronic ® f68 gel carrier for antibiotics in contaminated wound treatment. Am J Emerg Med 1997; 15: 20-24.
11. Qiu B, et al. A hydrogel prepared by in situ cross-linking ofa thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 2003; 24: 11-18.
12. Kopeček J,. Smart and genetically engineered biomaterials and drug delivery systems. Eur J Pharm Sci 2003; 20: 1-16.
13. Abashzadeh S, et al. Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate. Eur J Pharm Sci 2011; 44: 514-521.
14. Escobar-Chávez J, et al. Applications of thermo-reversible pluronic f-127 gels in pharmaceutical formulations. J Pharm Pharmaceut Sci 2006; 9: 339-358.
15. Koffi A, et al. Modulation of the rheological and mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended for the rectal administration of quinine. Eur J Pharm Sci 2006; 27: 328-335.
16. Ruel-Gariépy E, Leroux J-C,. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58: 409-426.
17. Ito T, et al. Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone. Biomaterials 2007; 28: 1778-1786.
18. Hubbell JA,. Hydrogel systems for barriers and local drug delivery in the control of wound healing. J Controlled Release 1996; 39: 305-313.
19. Gilbert JC, et al. The effect of solutes and polymers on the gelation properties of pluronic f-127 solutions for controlled drug delivery. J Controlled Release 1987; 5: 113-118.
20. Miller SC, Drabik BR,. Rheological properties of poloxamer vehicles. Int J Pharm 1984; 18: 269-276.
21. Dumortier G, et al. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 2006; 23: 2709-2728.
22. Bromberg LE, Ron ES,. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv Drug Deliv Rev 1998; 31: 197-221.
23. Ricci E, et al. Rheological characterization of poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci 2002; 17: 161-167.
24. Ur-Rehmann T, et al. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm 2010; 409: 19-29.
25. Barichello JM, et al. Absorption of insulin from pluronic f-127 gels following subcutaneous administration in rats. Int J Pharm 1999; 184: 189-198.
26. Veyries M, et al. Controlled release of vancomycin from poloxamer 407 gels. Int J Pharm 1999; 192: 183-193.
27. Liu Y, et al. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur J Pharm Sci 2009; 37: 306-312.
28. Cafaggi S, et al. Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation. Eur J Pharm Sci 2008; 35: 19-29.
29. Pec E, et al. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-630.
30. Wei G, et al. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Controlled Release 2002; 83: 65-74.
31. Chen J, et al. Mechanical, rheological and release behaviors of a poloxamer 407/poloxamer 188/carbopol 940 thermosensitive composite hydrogel. Molecules 2013; 18: 12415-12425.
32. Seo H, Kim J,. Effects of additives on phase transitions of poloxamer407/poloxamer 188 mixture and release property of monoolein cubic phase containing the poloxamers. J Ind Eng Chem 2012; 18: 88-91.
33. Schmolka IR,. Artificial skin I. Preparation and properties of pluronic f-127 gels for treatment of burns. J Biomed Mater Res 1972; 6: 571-582.
34. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
35. Cabana A, et al. Study of the gelation process of polyethylene oxidea-polypropylene oxideb-polyethylene oxidea copolymer (poloxamer 407) aqueous solutions. J Colloid Interface Sci 1997; 190: 307-312.
36. 12. Part i: preformulation study. Int J Pharm 2004; 270: 37-45.
37. Tung I,. Rheological behavior of poloxamer 407 aqueous solutions during sol-gel and dehydration processes. Int J Pharm 1994; 107: 85-90.
38. Xuan J, et al. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int J Pharm 2010; 395: 317-323.
39. Chirio D, et al. Thermosensitive gels for the topical administration of diltiazem. J Dispersion Sci Technoly 2011; 32: 320-325.
40. Liu Y, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive pluronic® f127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J Controlled Release 2007; 117: 387-395.
41. Edsman K, et al. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998; 6: 105-112.
42. Du L, et al. A multifunctional in situ-forming hydrogel for wound healing. Wound Repair Regen 2012; 20: 904-910.
43. Baloglu E, et al. Rheological and mechanical properties of poloxamer mixtures as a mucoadhesive gel base. Pharm Dev Technol 2011; 16: 627-636.
44. Cho K, et al. Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. Int J Pharm 2002; 260: 83-93.
45. Prestwich G, Vercruysse K,. Therapeutic applications of hyaluronic acid and hyaluronan derivatives. PSTT 1998; 1: 42-43.
46. Mayol L, et al. A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties. Eur J Pharm Biopharm 2007; 70: 199-206.
47. Pandit N, Wang D,. Salt effects on the diffusion and release rate of propranolol from poloxamer 407 gels. Int J Pharm 1998; 167: 183-189.
48. Schneider LA, et al. Influence of ph on wound-healing: a new perspective for wound-therapy? Arch Dermatol Res 2007; 298: 413-420.
49. Diegelmann RF, Evans MC,. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283-289.
50. Hiwale P, et al. In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium. Biomacromolecules 2011; 12: 3186-3193.
51. Indig FE, et al. Investigation of neutral endopeptidases (ec 3.4. 24.11) and of neutral proteinases (ec 3.4. 24.4) using a new sensitive two-stage enzymatic reaction. FEBS Lett 1989; 255: 237-240.
52. Vilcinskas A,. Coevolution between pathogen-derived proteinases and proteinase inhibitors of host insects. Virulence 2010; 1: 206-214